10:10 AM EDT, 08/20/2025 (MT Newswires) -- Keros Therapeutics ( KROS ) said Wednesday that KER-065 was granted orphan drug designation by the US Food and Drug Administration for the treatment of Duchenne muscular dystrophy.
Keros said it plans to advance the treatment to a phase 2 clinical trial.
Price: 14.54, Change: +0.05, Percent Change: +0.35